logo
Sellafield could leak until 2050s, MPs warn

Sellafield could leak until 2050s, MPs warn

Yahoo4 days ago

The UK's largest nuclear site could continue leaking radioactive water until the 2050s, MPs have warned, while its clean-up operations struggle to progress quickly enough.
The Public Accounts Committee (PAC) criticised the speed of decommissioning work at Sellafield in Cumbria, citing "cost overruns and continuing safety concerns" in a report published on Wednesday.
Although the committee noted there were "signs of improvement", PAC chairman Sir Geoffrey Clifton-Brown said Sellafield continued to present "intolerable risks".
The Nuclear Decommissioning Authority (NDA) acknowledged the leak at its Magnox Swarf Storage Silo (MSSS) was its "single biggest environmental issue".
The MSSS, which the NDA described as "the most hazardous building in the UK", has been leaking radioactive water into the ground since 2018, releasing enough to fill an Olympic swimming pool every three years.
It is likely to continue leaking until the oldest section of the building has been emptied in the 2050s, about a decade later than previously expected.
Sir Geoffrey said: "As with the fight against climate change, the sheer scale of the hundred-year timeframe of the decommissioning project makes it hard to grasp the immediacy of safety hazards and cost overruns that delays can have.
"Every day at Sellafield is a race against time to complete works before buildings reach the end of their life.
"Our report contains too many signs that this is a race that Sellafield risks losing."
Pointing to the fact that Sellafield Ltd had missed most of its annual targets for retrieving waste from buildings, including the MSSS, the committee warned: "The consequence of this underperformance is that the buildings are likely to remain extremely hazardous for longer."
A spokeswoman for the NDA said the "leak in the Magnox Swarf Storage Silo is contained and does not pose a risk to the public".
"Regulators accept that the current plan to tackle the leak is the most effective one."
Sir Geoffrey said it was of "vital importance that the government grasp the daily urgency of the work taking place at Sellafield and shed any sense of a far-off date of completion for which no-one currently living is responsible".
"Sellafield's risks and challenges are those of the present day.
"There are some early indications of some improvement in Sellafield's delivery, which our report notes.
"The government must do far more to hold all involved immediately accountable to ensure these do not represent a false dawn, and to better safeguard both the public purse and the public itself."
Sellafield ceased generating electricity in 2003 and, in addition to work cleaning up the site, now processes and stores nuclear waste from power plants around the UK.
The government plans to create an underground geological disposal facility (GDF) to store nuclear waste for the thousands of years it will take to become safe.
But the committee said delays in creating the GDF, which is now not expected to be complete until the late 2050s, meant more costs for Sellafield.
NDA chief executive David Peattie said it welcomed the report, adding it took the "findings seriously and the safety of the site and the wellbeing of our people will always be our highest priorities".
"We are pleased they recognise improvements in delivering major projects and that we are safely retrieving waste from all four highest hazard facilities."
The PAC expressed concern there was a "sub-optimal culture" at Sellafield and called on the NDA to publish information about the prevalence and perception of bullying in its annual report.
The NDA spokeswoman said: "We're committed to an open and respectful culture and we've taken decisive action to enable this, including strengthening our whistleblowing policy."
The Department for Energy Security and Net Zero said it "expected the highest standards of safety and security as former nuclear sites are dismantled, and the regulator is clear that public safety is not compromised at Sellafield".
"This is underpinned by monthly performance reviews and increased responsibility for overseeing major project performance, enabling more direct scrutiny and intervention," a spokeswoman for the department said.
"We have zero tolerance of bullying, harassment and offensive behaviour in the workplace - we expect Sellafield and the NDA to operate on this basis, investigate allegations and take robust action when needed."
Follow BBC Cumbria on X, Facebook, Nextdoor and Instagram.
Leak is Sellafield's 'biggest environmental issue'
GMB warns over potential nuclear plant Budget cuts
Nuclear site runs up 'considerable' costs - report
Plan for new building to store radioactive waste
Sellafield Ltd
Public Accounts Committee

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

What eating foods like dark chocolate and berries did to a study group of more than 120,000 people
What eating foods like dark chocolate and berries did to a study group of more than 120,000 people

Yahoo

time39 minutes ago

  • Yahoo

What eating foods like dark chocolate and berries did to a study group of more than 120,000 people

A new study reveals what drinking tea and eating dark chocolate and berries did for a group of more than 120,000 people. Those foods, as well as fruits like grapes, apples, oranges, and beverages like red wine, all contain flavonoids, which are compounds found in many plant products. Flavonoids can 'help your body function more efficiently while protecting it against everyday toxins and stressors,' per Healthline. The study's authors said those who consumed a diverse range of foods containing flavonoids (such as berries, grapes and dark chocolate) 'could lower their risk of developing serious health conditions and have the potential to live longer,' in a news release. The study has been peer-reviewed. In the study, which was recently published in the journal Nature Food, researchers observed 124,805 participants between the ages of 40 and 70 from the UK Biobank, a large-scale database with biomedical information. The participants were tracked for roughly 10 years and their dietary information was collected using a questionnaire asking them about the frequency in which they ate approximately 200 types of food and 30 beverages. Dr. Benjamin Parmenter, a research fellow at Edith Cowan University in Australia, was the study's first author and co-lead. He said consuming roughly 500 mg of flavonoids a day or more was linked to a 16 per cent lower risk of 'all-cause mortality' (meaning death from any cause). It was also linked to a roughly 10 per cent lower risk of cardiovascular disease, type 2 diabetes, and respiratory disease. A study published in 2025 in peer-reviewed food science journal Foods said, as it pertains to human health, 'flavonoids are recognized for their ability to combat aging, mitigate inflammation, safeguard the nervous system, and promote overall well-being.' However, in another study published in 2022 in the Nutrition Journal, researchers 'observed an increased risk of prostate cancer by higher intake of total flavonoids.' In a study published in 2016 in the Journal of Nutritional Science, researchers called for further studies on flavonoids so their usefulness 'in the diet could be improved for better human health.' 'Over 30 different types of flavonoids are regularly consumed in the human diet. These are found in different types of everyday foods,' Parmenter told National Post over email. A few squares of dark chocolate could be roughly 25 mg of flavonoids. One apple is equal to roughly 100 mg of flavonoids, while one orange is roughly 60 mg. For tea drinkers, one cup of black tea is roughly 300 mg of flavonoids, while the same amount of green tea is roughly 150 mg. 'We observed that consuming a higher quantity and wider diversity of dietary flavonoids, when consumed together, may represent the optimal approach for improving long-term health, compared with increasing either flavonoid quantity or diversity alone,' Parmenter said. Those with the highest flavonoid diversity were more likely to be female, older, have a lower body mass index (BMI), be more physically active and have a higher education and were less likely to be current smokers, according to the study. 'We also know from lab data and clinical studies that different flavonoids work in different ways, some improve blood pressure, others help with cholesterol levels and decrease inflammation,' said study co-lead professor Aedín Cassidy, per the news release. Cassidy is from the Co-Centre for Sustainable Food Systems and Institute for Global Food Security at Queen's University Belfast. The findings of the study show how 'simple and achievable dietary dietary swaps' can 'potentially improve health in the long-term,' she said. 'Dietary swaps, such as drinking more tea and eating more berries and apples for example, can help increase the variety and intake of flavonoid-rich foods, and potentially improve health in the long-term,' said Cassidy. According to researchers, no previous works appear to have reported on the human health benefits of a flavonoid-diverse diet. 'Consequently, replication of our findings in other cohorts and clinical trials will be critical, as will the exploration of flavonoid diversity with other disease outcomes. Interpretation, however, requires careful consideration,' said researchers, in the study. The study was led by researchers from Queen's University Belfast, Edith Cowan University Perth, and the Medical University of Vienna and Universitat Wien. Smoking one cigarette equals 20 minute off your life, study finds What drinking 3 cups of coffee daily did to a study group of more than 170,000 people Our website is the place for the latest breaking news, exclusive scoops, longreads and provocative commentary. Please bookmark and sign up for our daily newsletter, Posted, here.

Andrew Malkinson ‘not finished' fighting for reform after wrongful conviction
Andrew Malkinson ‘not finished' fighting for reform after wrongful conviction

Yahoo

timean hour ago

  • Yahoo

Andrew Malkinson ‘not finished' fighting for reform after wrongful conviction

Andrew Malkinson, who spent 17 years in prison for a rape he did not commit, says his fight to reform the legal system's handling of miscarriages of justice is far from over. The 59-year-old had his conviction overturned in 2023 after years protesting his innocence. Mr Malkinson, who told The Sunday Times his 'life was desolated' by the wrongful conviction, says he is determined to change the justice system, starting with the Criminal Cases Review Commission (CCRC). 'I haven't finished. I want to change a lot more,' he said. 'It's a good feeling that something so dreadful and tragic is leading to real change.' It comes amid news Dame Vera Baird KC will become the interim chairwoman of the CCRC. The barrister will take up the post from June 9 until December 8 next year, and is tasked with carrying out an urgent review into the running of the independent body and making sure lessons have been learnt from previous cases. Mr Malkinson said he remained 'incandescent' at the CCRC, as well as the Government's compensation scheme, which makes it difficult for wrongly-convicted people to receive payouts. 'This is an assault on innocent people,' he said. 'It's an assault on the public, because any member of the public could end up where I was. Anybody could be the next victim, because there will be more.' Despite having his conviction quashed in 2023, he had to wait until February to get his first compensation payment. Mr Malkinson had been living on benefits and food banks from his release until then. Under the 2014 Antisocial Behaviour, Crime and Policing Act, payments are only awarded to people who can prove innocence beyond a reasonable doubt. Ministry of Justice data showed that only 6.5% of people who had applied for compensation due to a miscarriage of justice between April 2016 and March 2024 were awarded payouts. Of 591 people who applied, 39 were granted compensation. Figures showed that 35 have since received money, with average amounts totalling £68,000. In a statement in February, lawyer Toby Wilton welcomed the payment, but said the £1 million cap on compensation payouts should be lifted. This is currently the maximum amount that can be paid to victims of miscarriages of justice who are wrongly jailed for at least 10 years. 'The Government should lift the current cap on compensation, and end the twisted quirk that whilst awards under other compensation schemes are excluded from assessment for benefits,' he said.

Coherus BioSciences, Inc. (CHRS): A Bull Case Theory
Coherus BioSciences, Inc. (CHRS): A Bull Case Theory

Yahoo

timean hour ago

  • Yahoo

Coherus BioSciences, Inc. (CHRS): A Bull Case Theory

We came across a bullish thesis on Coherus BioSciences, Inc. (CHRS) on Steve Wagner's Substack. In this article, we will summarize the bulls' thesis on CHRS. Coherus BioSciences, Inc. (CHRS)'s share was trading at $0.77 as of 30th May. CHRS's trailing P/E was 1.77 according to Yahoo Finance. Scientist in a lab working on a research project, focusing on biotechnology and healthcare advancements. Coherus BioSciences (CHRS), long overlooked by Wall Street, is taking a bold step into innovative oncology by partnering with UK-based STORM Therapeutics to test a novel cancer treatment strategy. The collaboration brings together Coherus's immunotherapy toripalimab (LOQTORZI) and STORM's first-in-class RNA-modifying enzyme inhibitor STC-15 in a Phase 1b/2 clinical trial. This unexpected pairing represents a fresh approach to immuno-oncology, targeting cancer through dual mechanisms that could produce synergistic effects. Toripalimab, already approved in the U.S. for nasopharyngeal carcinoma and under review for broader indications, offers proven checkpoint inhibition, while STC-15 introduces a cutting-edge method of disrupting RNA methylation processes linked to tumor growth and immune evasion. If this combo demonstrates efficacy, it could represent a completely new class of cancer therapy and place Coherus at the forefront of next-generation immuno-oncology innovation. Importantly, this partnership shows strategic vision from CHRS's management as they seek to differentiate the company beyond biosimilars and move deeper into proprietary immunotherapy. With the trial still in early stages and little market attention so far, the risk/reward profile for investors is potentially skewed to the upside. Should the data prove positive, the impact could be significant for both companies, especially for CHRS as it repositions itself as a serious player in oncology innovation. This under-the-radar development deserves close monitoring, as it could catalyze a major reevaluation of Coherus's valuation and growth trajectory. Previously, we have covered CHRS in March 2025 wherein we summarized a by the same author. Coherus BioSciences (CHRS) posted a strong turnaround in 2024 with $267M in revenue and $28.5M net income, driven by Loqtorzi's growth and the planned $250M Udenyca divestiture. The company pivoted fully to oncology, trimmed costs, and advanced its pipeline, yet management expressed frustration over the stock's undervaluation, hinting at potential M&A. Since our last coverage, the stock is down 38% as of 30th May. We don't trust CHRS' management as the stock lost more than 95% of its value in recent years and is still losing a ton of money. The market agrees with us and thinks this stock is going to go bankrupt. We believe CHRS should stop wasting shareholder's money, sell valuable assets, and liquidate the company. We don't think that's a likely outcome. Coherus BioSciences, Inc. (CHRS) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 10 hedge fund portfolios held CHRS at the end of the first quarter which was 10 in the previous quarter. While we acknowledge the potential of CHRS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store